4//SEC Filing
BioLexis Pte Ltd. 4
Accession 0001209191-19-022631
CIK 0001649989other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 5:01 PM ET
Size
10.5 KB
Accession
0001209191-19-022631
Insider Transaction Report
Form 4
GMS Tenshi Holdings Pte. Ltd
DirectorChief Executive Officer10% Owner
Transactions
- Other
Series A-1 Convertible Preferred Stock
2019-03-31+1,542→ 63,250 total→ Common Stock (29,140 underlying)
Pillai Arun Kumar
Director10% Owner
Transactions
- Other
Series A-1 Convertible Preferred Stock
2019-03-31+1,542→ 63,250 total→ Common Stock (29,140 underlying)
Sukhtian Ghiath M.
Director10% Owner
Transactions
- Other
Series A-1 Convertible Preferred Stock
2019-03-31+1,542→ 63,250 total→ Common Stock (29,140 underlying)
Footnotes (4)
- [F1]Each share of the Series A-1 Convertible Preferred Stock (the "Series A-1") is convertible into shares of the Issuer's common stock, par value $0.01 per share ("Shares") at any time at the election of the holder. The Series A-1 has no expiration date.
- [F2]Represents shares of Series A-1 received by BioLexis Pte Ltd. ("BioLexis") as a payment-in-kind dividend on previously acquired Series A-1.
- [F3]These securities are held of record by BioLexis. Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.
- [F4]By virtue of the relationships described above in Footnote 3, Kumar and Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
IncorporatedSingapore
Related Parties
1- filerCIK 0001716335
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 5:01 PM ET
- Size
- 10.5 KB